HOME >> BIOLOGY >> NEWS
Other highlights in the May 5 JNCI

Selenium May Slow Prostate Cancer Tumor Progression

Higher plasma selenium levels are associated with a decreased risk of advanced prostate cancer, according to a new study. This may indicate that higher selenium levels could slow prostate cancer tumor progression.

Haojie Li, M.D., Ph.D., of Brigham and Women's Hospital and Harvard Medical School, and colleagues analyzed plasma samples, obtained in 1982, from a subset of healthy men enrolled in the Physicians' Health Study, some of whom were diagnosed with prostate cancer during the subsequent 13 years. The researchers found that higher plasma selenium levels were associated with a decreased risk of subsequent advanced prostate cancer. Among men who had increased prostate-specific antigen (PSA) levels in 1982, the researchers also found an association between higher selenium levels and a reduced risk of all prostate cancer.

In an editorial, Scott M. Lippman, M.D., of The University of Texas M. D. Anderson Cancer Center in Houston, and colleagues give an overview of research on selenium's effects on prostate cancer. This new study, they write, continues "to support the initial impression of this agent's tremendous potential as a prostate cancer preventative agent."

Contact: Amy Dayton, Brigham and Women's Hospital, 617-534-1603, adayton2@partners.org

Researchers Identify Possible New Target for Inhibiting Tumor Angiogenesis

Inactivating the mRNA for c-Jun, a transcription factor, inhibits angiogenesis--the development of new blood vessels--and tumor growth in rodent models, according to a new study.

Levon M. Khachigian, Ph.D., of The University of New South Wales in Sydney, Australia, and colleagues suppressed expression of c-Jun in microvascular endothelial cells (the cells that line blood vessels) by transfecting them with a DNA enzyme (DNAzyme) targeting c-Jun mRNA, and studied the properties of the
'"/>

Contact: Sarah Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
4-May-2004


Page: 1 2 3 4 5

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2019)... ... November 19, 2019 , ... Project Lifeline – a community partnership ... to address substance use disorder (SUD) – will take center stage at ... to the program’s effectiveness in preventing and treating opioid abuse in Blair County, Pennsylvania, ...
(Date:11/14/2019)... ... 2019 , ... NDA Partners Chairman Carl Peck, MD ... program management executive with more than 33 years of regulatory and product development ... an Expert Consultant. , Robert Peterson has extensive experience in formulating and ...
(Date:11/12/2019)... ... November 12, 2019 , ... G5, the leader in ... performance up to 25% and reduces cost-per-click by as much as 15%. An ... attribution (MTA) to predict best advertising outcomes and automatically allocate daily ad investments ...
Breaking Biology News(10 mins):
(Date:10/30/2019)... ... October 30, 2019 , ... Western University of ... innovation and technology play in educating the next generation of health care providers. ... and presentations by WesternU administrators and representatives of companies working with the University ...
(Date:10/26/2019)... ... October 24, 2019 , ... Sparks Marketing ... Group (BMMG), a boutique healthcare-specific marketing firm, to strengthen the agency’s growing ... Strategy Division. , Healthcare clients in pharma, bio-therapeutics, medical device and healthcare technologies ...
(Date:10/22/2019)... ... October 22, 2019 , ... DermBiont, a clinical stage microbiome ... met its primary safety endpoints, with no application site reactions and no adverse ... treatment of interdigital tinea pedis (athlete’s foot). Additionally, the trial demonstrated a clinical ...
(Date:10/10/2019)... (PRWEB) , ... October 09, 2019 , ... ... Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote speaker ... October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist and ...
Breaking Biology Technology:
Cached News: